January 19, 2018 / 1:15 PM / in 9 months

BRIEF-Albireo Pharma Says Elobixibat Approved In Japan For Treatment Of Chronic Constipation

Jan 19 (Reuters) - Albireo Pharma Inc:

* ALBIREO TO RECEIVE MORE THAN $55 MILLION(1) IN NONDILUTIVE CASH PAYMENTS

* ALBIREO PHARMA INC - ELOBIXIBAT APPROVED IN JAPAN FOR TREATMENT OF CHRONIC CONSTIPATION

* ALBIREO PHARMA - JAPAN'S MINISTRY OF HEALTH, LABOR & WELFARE APPROVED NEW DRUG APPLICATION FOR ELOBIXIBAT FOR TREATMENT OF CHRONIC CONSTIPATION IN JAPAN

* ALBIREO PHARMA INC - APPROVAL OF ELOBIXIBAT IN JAPAN TRIGGERS PAYMENTS TO ALBIREO SUBSIDIARY ELOBIX AB FROM EA PHARMA CO LTD

* ALBIREO PHARMA - CO ‍EXPECTS TO INITIATE A PLANNED PHASE 3 STUDY OF A4250 BY SPRING OF 2018​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below